Congestive Heart Failure News and Research

RSS

Congestive Heart Failure is a condition in which the heart can't pump blood the way it should. In some cases, the heart can't fill with enough blood. In other cases, the heart can't send blood to the rest of the body with enough force. Some people have both problems. "Heart failure" doesn't mean that your heart has stopped or is about to stop working. However, it's a serious condition that requires medical care. Heart failure develops over time as the pumping of the heart grows weaker. It can affect the right side of the heart only or both the left and right sides of the heart. Most cases involve both sides of the heart.

Medical report showing the devastating impacts of coal on human body released

Physicians for Social Responsibility today released a groundbreaking medical report, "Coal's Assault on Human Health," which takes a new look at the devastating impacts of coal on the human body.

23 Nov 2009

Employers take action to improve medication adherence

More employers are taking steps to improve their employees' health by making sure they take their medicines as prescribed, a move that could stave off more serious and costly health consequences, according to a new report sponsored by the National Pharmaceutical Council (NPC).

21 Nov 2009

Publicly released report cards do not appear to improve hospitals' performance, says new study

An analysis of quality of cardiac care following the public release of data on measures of care at hospitals in Ontario, Canada, did not result in significant systemwide improvement in hospitals' performance on most quality of care indicators, according to a study to be published in the December 2 issue of JAMA. The study is being released early online because of its presentation at an American Heart Association scientific conference.

19 Nov 2009

Homecare, an important part of the solution to nation's healthcare crisis

During November -- National Homecare Month -- the American Association for Homecare celebrates the thousands of dedicated professionals who provide cost-effective and consumer-preferred homecare.

18 Nov 2009

Health Net’s MA product portfolio offers budget-friendly health plan choices to beneficiaries for 2010

With the kick-off of the Medicare Annual Election Period (AEP) this week, Health Net, Inc. reminds those eligible for Medicare that Health Net’s Medicare Advantage (MA) product portfolio offers a comprehensive range of budget-friendly health plan choices to beneficiaries for 2010.

17 Nov 2009

Genentech submits sBLAs to the FDA for Avastin

Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.

17 Nov 2009

Stem cell therapy to treat heart, lung and vascular diseases show positive results

A Florida cardiologist is using stem cell therapy to treat patients who suffer from a range of heart, lung and vascular illnesses. The results have been extraordinary.

16 Nov 2009

Study of GBHN Order Set project reveals improvements in the length of stay and ordering of best practices

A study of the Grey Bruce Health Network (GBHN) Order Set project has revealed impressive improvements in the length of stay and ordering of best practices.

13 Nov 2009

Third-quarter 2009 results announced by Response Biomedical

Response Biomedical Corporation today announced financial results for the third quarter and nine months ended September 30, 2009.

10 Nov 2009

Average cost of patient deaths much higher than patients who were discharged alive

One of every three people who died in 2007 in the United States were in the hospital for treatment at the time of their deaths, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. The cost of their hospital stays was about $20 billion.

6 Nov 2009

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

Acorda Therapeutics, Inc. today announced its financial results for the third quarter of 2009.

3 Nov 2009

Amgen publishes Phase 3 study results of Aranesp

Amgen today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes.

31 Oct 2009

Nonin Medical receives Medical Technology Award for Onyx II, Model 9560

Nonin Medical, Inc., a leading innovator of noninvasive physiological monitoring solutions, was awarded the Medical Technology Award and its owner and CTO, Phil Isaacson received the Technology Executive of the Year by the Minnesota High Tech Association (MHTA), in partnership with Enterprise Minnesota and LifeScience Alley.

30 Oct 2009

Cardiome Pharmam, Astellas Pharma begin patient enrolment for ACT 5 trial

Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that patient enrolment has begun for the ACT 5 trial, a confirmatory Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection, a drug product candidate under development for the rapid conversion of atrial fibrillation to sinus rhythm.

29 Oct 2009

NeoChord commences patient enrollment in its TACT European clinical trial

NeoChord, Inc., a venture-backed, Minneapolis-based medical technology company, announced today that it has enrolled the first patient in its European clinical trial. The trial, known as TACT (transapical artificial chordae tendineae) is being conducted in Germany, Denmark, Czech Republic and Norway.

28 Oct 2009

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study.

28 Oct 2009

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

NovaDel Pharma Inc., has entered into a licensing agreement with privately-held Mist Acquisition, LLC to manufacture and commercialize the NitroMist® lingual spray version of nitroglycerine, a widely-prescribed and leading short-acting nitrate for the treatment of angina pectoris.

28 Oct 2009

Hyperion Therapeutics enrolls first patient in HPN-100 phase III clinical trial for urea cycle disorders

Hyperion Therapeutics today announced that the first patient has been enrolled in its pivotal phase III clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The 4-week, multi-center, randomized, double-blind, cross-over study is designed to evaluate the non-inferiority of glycerol phenylbutyrate to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder in adults with urea cycle disorders.

27 Oct 2009

New data from efficacy study of CIMZIA in Crohn's disease patients presented

New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.

27 Oct 2009

Canadian cardiologists, oncologists team up to fight breast cancer

A team of Canadian cardiologists, in collaboration with oncologists, are playing an important role in the war against breast cancer Dr. Michael McDonald told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

26 Oct 2009

Congestive Heart Failure News and Research

Medical report showing the devastating impacts of coal on human body released

Employers take action to improve medication adherence

Publicly released report cards do not appear to improve hospitals' performance, says new study

Homecare, an important part of the solution to nation's healthcare crisis

Health Net’s MA product portfolio offers budget-friendly health plan choices to beneficiaries for 2010

Genentech submits sBLAs to the FDA for Avastin

Stem cell therapy to treat heart, lung and vascular diseases show positive results

Study of GBHN Order Set project reveals improvements in the length of stay and ordering of best practices

Third-quarter 2009 results announced by Response Biomedical

Average cost of patient deaths much higher than patients who were discharged alive

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

Amgen publishes Phase 3 study results of Aranesp

Nonin Medical receives Medical Technology Award for Onyx II, Model 9560

Cardiome Pharmam, Astellas Pharma begin patient enrolment for ACT 5 trial

NeoChord commences patient enrollment in its TACT European clinical trial

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

Hyperion Therapeutics enrolls first patient in HPN-100 phase III clinical trial for urea cycle disorders

New data from efficacy study of CIMZIA in Crohn's disease patients presented

Canadian cardiologists, oncologists team up to fight breast cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News